Biocon

₹373.6 4.6 | 1.2%

WEBSITE BSE:532523 NSE : BIOCON LTD. 09 Jul, 15:57

Market Cap ₹49942 Cr.

Stock P/E 38.5

P/B 1.9

Current Price ₹373.6

Book Value ₹ 195.5

Face Value 5

52W High ₹404.6

Dividend Yield 0.13%

52W Low ₹ 290.8

Edit Ratio

Biocon Research see more...

Overview Inc. Year: 1978Industry: Pharmaceuticals & Drugs

Biocon Limited is an India-based biopharmaceutical company that focuses to deal with diabetes, cancers and autoimmune diseases. The Company is likewise focused on developing novel treatments for diabetes, oncology and immunology. The Company's corporations section includes Generics, Biosimilars, Novel Biologics and Research Services. The Company's Generic Formulations and API products consist of Rosuvastatin, Mycophenolate Mofetil (MMF), Glatiramer Acetate, Fingolimod, Teriflunomide, Dasatinib, Lenalidomide, Pazopanib, Erdafitinib Orlistat, Mirabegron, Simvastatin, Atorvastatin, Fingolimod, Dapagliflozin, Pemetrexed, Simvastatin, Atorvastatin, Rosuvastatin, Dabigatran, Apixaban, Vildagliptin, Linagliptin, Empagliflozin, Repaglinide, Liraglutide, Sirolimus, Pimecrolimus, Posaconazole, Micafungin, Anidulafungin and Brinzolamide. The Company's portfolio consists of ALZUMAb-L (Itolizumab), RemWin (Remdesivir), ARAFLU (Favipiravir) and CytoSorb.

Biocon Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Biocon Quarterly Results

#(Fig in Cr.)	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Net Sales	2941	3774	3423	3462	3954	3917	3433	3590	3821	4417
Other Income	79	155	94	158	566	49	1135	33	35	37
Total Income	3020	3929	3516	3620	4519	3966	4567	3623	3856	4454
Total Expenditure	2297	2777	2708	2721	3027	3001	2813	2905	3070	3339
Operating Profit	723	1152	808	900	1492	965	1755	718	787	1115
Interest	120	249	233	248	267	227	236	226	223	212
Depreciation	301	364	358	389	415	407	405	420	425	436
Exceptional Income / Expenses	-271	-3	0	-24	21	-9	32	26	18	20
Profit Before Tax	30	537	217	239	832	322	1146	98	156	487
Provision for Tax	-5	82	35	42	55	96	284	71	75	27
Profit After Tax	35	455	182	197	777	226	862	27	81	459
Adjustments	-77	-141	-81	-71	-117	-90	-202	-43	-56	-115
Profit After Adjustments	-42	313	101	126	660	136	660	-16	25	345
Adjusted Earnings Per Share	-0.3	2.6	0.8	1	5.5	1.1	5.5	-0.1	0.2	2.9

Biocon Profit & Loss

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Net Sales	2877	3090	3347	3891	4123	5514	6301	7143	8184	11174	14756	15261
Other Income	245	215	231	285	381	414	508	605	690	768	968	1240
Total Income	3123	3305	3579	4177	4504	5929	6808	7748	8874	11942	15723	16500
Total Expenditure	2380	2556	2732	3040	3469	4391	5044	5841	6691	9055	11559	12127
Operating Profit	743	749	847	1137	1035	1538	1765	1907	2183	2888	4164	4375
Interest	2	9	29	26	62	71	65	58	68	419	974	897
Depreciation	204	221	249	277	385	448	552	715	814	1113	1569	1686
Exceptional Income / Expenses	0	105	161	0	0	195	68	13	-111	-291	-12	96
Profit Before Tax	538	624	751	850	610	1215	1215	1068	983	897	1525	1887
Provision for Tax	107	96	142	162	157	212	315	222	212	254	227	457
Profit After Tax	431	528	609	688	453	1003	900	846	772	643	1298	1429
Adjustments	-17	-31	-59	-76	-81	-97	-152	-106	-123	-180	-275	-416
Profit After Adjustments	414	497	550	612	372	905	748	741	648	463	1023	1014
Adjusted Earnings Per Share	3.4	4.1	4.6	5.1	3.1	7.5	6.2	6.2	5.4	3.9	8.5	8.5

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	32%	27%	22%	18%
Operating Profit CAGR	44%	30%	22%	19%
PAT CAGR	102%	15%	5%	12%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	3%	4%	-2%	17%
ROE Average	7%	7%	10%	13%
ROCE Average	7%	7%	9%	12%

Biocon Balance Sheet

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Shareholder's Funds	3027	3271	4034	4838	5181	6098	6706	7627	8433	17867	19784
Minority's Interest	82	172	266	376	468	609	677	881	1038	4622	5491
Borrowings	606	770	2072	2108	1790	1526	1222	2962	3999	15291	12932
Other Non-Current Liabilities	656	608	349	196	217	597	1463	2535	2804	5452	2187
Total Current Liabilities	1380	1555	1666	1678	2141	3039	4008	4210	3828	8511	15359
Total Liabilities	5751	6375	8387	9197	9796	11868	14076	18215	20101	51742	55753
Fixed Assets	1525	1630	1748	3625	3700	4471	5971	6364	6569	29468	30644
Other Non-Current Assets	1587	2183	2667	1524	1948	2508	2780	4250	5149	9940	9931
Total Current Assets	2639	2563	3971	4048	4149	4889	5325	7600	8382	12334	15179
Total Assets	5751	6375	8387	9197	9796	11868	14076	18215	20101	51742	55753

Biocon Cash Flow

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Opening Cash & Cash Equivalents	474	557	458	758	710	449	659	825	897	654	1300
Cash Flow from Operating Activities	561	211	371	640	662	1155	1283	1160	1177	1853	2954
Cash Flow from Investing Activities	-938	-509	-1142	-499	-684	-714	-1559	-3625	-1699	-14282	-1005
Cash Flow from Financing Activities	426	186	1068	-178	-240	-242	388	2564	242	13049	-2333
Net Cash Inflow / Outflow	49	-112	297	-36	-262	199	112	99	-280	619	-383
Closing Cash & Cash Equivalent	557	463	758	710	449	659	825	897	654	1295	920

Biocon Ratios

#	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Earnings Per Share (Rs)	3.45	4.15	4.59	5.1	3.1	7.54	6.24	6.17	5.4	3.85	8.52
CEPS(Rs)	5.29	6.25	7.15	8.04	6.99	12.09	12.1	13.01	13.21	14.63	23.88
DPS(Rs)	5	0.83	0.83	0.5	1	0.5	0	0	0.5	1.5	0.5
Book NAV/Share(Rs)	24.21	26.93	33.1	39.74	42.6	50.17	54.97	62.27	68.53	146.53	162.11
Core EBITDA Margin(%)	17.08	17.11	18.22	21.71	15.85	20.38	19.95	18.23	18.18	18.8	21.41
EBIT Margin(%)	18.51	20.27	23.09	22.33	16.26	23.32	20.31	15.76	12.8	11.67	16.74
Pre Tax Margin(%)	18.45	19.99	22.22	21.67	14.77	22.03	19.28	14.95	11.98	7.96	10.22
PAT Margin (%)	14.78	16.92	18.02	17.55	10.97	18.18	14.28	11.85	9.4	5.7	8.69
Cash Profit Margin (%)	21.77	24	25.37	24.61	20.3	26.3	23.05	21.86	19.32	15.57	19.2
ROA(%)	8.47	8.72	8.25	7.83	4.77	9.26	6.94	5.24	4.03	1.79	2.41
ROE(%)	15.68	17.22	16.91	15.74	9.17	18.01	14.26	12.03	9.83	4.98	7
ROCE(%)	15.75	15.3	14.33	12.83	9.21	16.12	14.35	10.56	8.3	5.37	7.03
Receivable days	69.48	80.09	80.16	74.35	86.05	77.96	72.86	70.03	79.49	91.14	119.85
Inventory Days	48.54	48.47	53.71	54.81	60	58.05	71.47	84.38	92.6	105.87	112.31
Payable days	106.58	112.86	146.96	170.25	194.65	212.04	231.48	230.92	209.62	271.55	376.86
PER(x)	20.5	18.88	17.52	37.04	95.74	40.49	43.4	66.25	61.95	53.54	31.01
Price/Book(x)	2.92	2.91	2.43	4.75	6.97	6.09	4.92	6.57	4.88	1.41	1.63
Dividend Yield(%)	1.18	1.06	1.04	0.26	0.17	0.16	0	0	0.15	0.73	0.19
EV/Net Sales(x)	2.97	3.1	3.16	6.15	8.87	6.89	5.41	7.19	5.29	3.59	3.06
EV/Core EBITDA(x)	11.49	12.78	12.49	21.05	35.35	24.71	19.32	26.93	19.85	13.9	10.85
Net Sales Growth(%)	15.77	7.39	8.34	16.24	5.97	33.73	14.26	13.37	14.57	36.54	32.05
EBIT Growth(%)	-12.76	17.35	23.32	12.18	-23.32	91.48	-0.47	-12.06	-6.64	25.26	89.92
PAT Growth(%)	-15.97	22.66	15.27	12.97	-34.15	121.28	-10.25	-5.96	-8.82	-16.67	101.84
EPS Growth(%)	-18.69	20.2	10.66	11.21	-39.16	143.1	-17.35	-1.03	-12.48	-28.64	120.99
Debt/Equity(x)	0.3	0.35	0.62	0.48	0.44	0.4	0.4	0.58	0.6	1.01	0.81
Current Ratio(x)	1.91	1.65	2.38	2.41	1.94	1.61	1.33	1.81	2.19	1.45	0.99
Quick Ratio(x)	1.64	1.37	2.09	2.14	1.61	1.29	0.97	1.36	1.59	0.95	0.67
Interest Cover(x)	317.29	71.12	26.64	33.68	10.92	18.14	19.72	19.5	15.54	3.14	2.57
Total Debt/Mcap(x)	0.1	0.12	0.26	0.1	0.06	0.07	0.08	0.09	0.12	0.72	0.5

Biocon Shareholding Pattern

#	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Promoter	60.64	60.64	60.64	60.64	60.64	60.64	60.64	60.64	60.64	60.64
FII	14.42	10.2	9.52	7.96	6.55	5.63	5.9	5.93	5.66	5.66
DII	8.63	11.9	12.59	14.08	14.51	13.68	14.3	14.44	15.36	15.72
Public	16.31	17.27	17.26	17.32	18.3	20.05	19.17	19	18.34	17.97
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Promoter	72.8	72.8	72.8	72.8	72.8	72.8	72.8	72.8	72.8	72.8
FII	17.31	12.25	11.43	9.56	7.87	6.76	7.08	7.11	6.79	6.8
DII	10.36	14.28	15.11	16.91	17.42	16.42	17.16	17.33	18.45	18.88
Public	19.58	20.73	20.72	20.79	21.97	24.07	23.01	22.81	22.02	21.58
Others	0	0	0	0	0	0	0	0	0	0
Total	120.06	120.06	120.06	120.06	120.06	120.06	120.06	120.06	120.06	120.06

Pros

Company has reduced debt.

Cons

Company has a low return on equity of 7% over the last 3 years.
Debtor days have increased from 271.55 to 376.86days.
The company has delivered a poor profit growth of 5% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Biocon News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Biocon

Add Watchlist

Biocon Research see more...

Overview Inc. Year: 1978Industry: Pharmaceuticals & Drugs

Biocon Share Price

Alert Data

Quarterly Price

Peer Comparison

Biocon Quarterly Results

Biocon Profit & Loss

Growth Rates

Biocon Balance Sheet

Biocon Cash Flow

Biocon Ratios

Biocon Shareholding Pattern

Biocon News

IPO

Sharescart: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!

Enter Your Complaint